Skip to main content

Peer Review reports

From: Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

Original Submission
17 Oct 2022 Submitted Original manuscript
23 Nov 2022 Reviewed Reviewer Report
1 Dec 2022 Reviewed Reviewer Report
18 Dec 2022 Author responded Author comments - Chao-Yuan Huang
Resubmission - Version 2
18 Dec 2022 Submitted Manuscript version 2
29 Dec 2022 Reviewed Reviewer Report
16 Jan 2023 Reviewed Reviewer Report
27 Feb 2023 Author responded Author comments - Chao-Yuan Huang
Resubmission - Version 3
27 Feb 2023 Submitted Manuscript version 3
16 Mar 2023 Reviewed Reviewer Report
28 Mar 2023 Author responded Author comments - Chao-Yuan Huang
Resubmission - Version 4
28 Mar 2023 Submitted Manuscript version 4
30 Mar 2023 Author responded Author comments - Chao-Yuan Huang
Resubmission - Version 5
30 Mar 2023 Submitted Manuscript version 5
24 Apr 2023 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
25 Apr 2023 Editorially accepted
20 Jun 2023 Article published 10.1186/s12885-023-10885-4

You can find further information about peer review here.

Back to article page